Insider Purchases: Inside the Buy
Tag: #FUNanc1al
🫀 Boston Scientific (BSX): The CEO Just Bought $9 Million. Is Wall Street Missing Something?
Boston Scientific's stock has been cut nearly in half from its peak, yet the business remains fundamentally strong. With CEO Mike Mahoney buying $9 million worth of shares, a remarkably low 0.71 PEG ratio, billions in annual free cash flow, and overwhelming institutional ownership, is Wall Street overlooking one of healthcare's most attractive GARP opportunities?
🌾 Bunge (BG): Why This Agribusiness Compounder Looks Attractive Again After a 43% Rally
Bunge isn't merely a grain trader—it's one of the world's most important agricultural infrastructure companies. After a 43% rally from our 2025 recommendation, a healthy pullback, another insider purchase, stronger earnings guidance and accelerating Viterra synergies make the long-term investment story compelling once again.
🧪 Huntsman (HUN): CEO Buys $981K as Wall Street Overlooks a $12 Billion Chemical Merger
Huntsman isn't simply a cyclical chemical company anymore. Between repeated insider buying, a transformational $12.5 billion merger with Olin, trading at just 0.64x book value and more than $400 million in projected synergies, investors may be looking at one of the market's more intriguing industrial turnaround opportunities.
🧬 Ionis Pharmaceuticals (IONS): The RNA Arbitrage — $2.1B Cash, $1M Insider Buy, and the Post-Trial Collapse
Ionis Pharmaceuticals (NASDAQ: IONS) lost billions in market value after a disappointing clinical trial—but one director immediately bought more than $1 million worth of shares. Is Wall Street missing the bigger RNA platform story? Here's the full analysis.
🛒 Albertsons (ACI): Wall Street Gave Up. One Executive Just Invested $1.96 Million.
Albertsons has disappointed Wall Street—but one executive just invested nearly $2 million of his own money. We examine the insider buy, valuation, operating cash flow, ACI Edge restructuring, dividend sustainability and whether ACI could become one of the market's more interesting turnaround stories.
❄️ Hudson Technologies (HDSN): The Entire Board Bought. Should Investors Pay Attention?
Hudson Technologies isn't the hottest stock on Wall Street—but it may be one of the coolest. After synchronized insider buying from management, directors and a major shareholder, we examine whether this overlooked refrigerant specialist deserves a closer look.
🥫 The Great Canned-Good Reset: Inside Conagra's Dividend Cut, Brase's $510K Skin-in-the-Game, and the 10x Forward P/E Floor
Conagra's 50% dividend cut shocked income investors—but the story didn't end there. With CEO John Brase buying more than $510,000 of stock, debt moving lower, and shares trading around 10x forward earnings, the turnaround thesis deserves another look.
⚛️ Standard Nuclear (NYSE: STDN): Fascinating Technology. Speculative Stock.
Standard Nuclear may help power tomorrow's AI-driven economy, but investing isn't about buying exciting technologies at any price. We examine STDN's IPO, Decisive Point's $19 million purchase, its impressive backlog, and why patience may be the smartest move.
🏥 Elevance Health (NYSE: ELV): The CEO Bought Again. We're Still Buying the Story.
Exactly one year after publishing our original bullish thesis on Elevance Health, we're revisiting the story. Shares are up nearly 26%, yet the core investment case remains surprisingly intact. CEO Gail Boudreaux just bought another $1 million worth of stock, institutions continue to hold over 93% of shares, and valuation still looks attractive.
🛢️ Occidental Petroleum (OXY) Stock Analysis: Warren Buffett's Favorite Oil Bet Just Got Even More Interesting
Is Occidental Petroleum one of the market's most misunderstood value stocks? With Warren Buffett owning more than a quarter of the company, a brand-new CEO buying shares, $7.1 billion of debt retired, and a carbon-capture business quietly emerging, OXY may be much more than just another oil producer.